|
Loading...
| ||||||||||||||
Recent Publications by AstraZeneca R&D: |  | |
| The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds.
The liver is the major organ metabolising drugs. The hepatocyte contains a... | Clinical Pharmacology and DMPK, AstraZeneca R&D, Molndal, Sweden. | Methods Mol Biol. 2010;640:375-87.
DOI Direct Link |
| 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
A class of inhibitors of mitogen activated protein kinase-activated kinase... | Department of Biological Sciences, AstraZeneca R&D Lund, S-22187 Lund, | Bioorg Med Chem Lett. 2010 Jun 25.
DOI Direct Link |
| Toxicological and Pathophysiological Roles of Reactive Oxygen and Nitrogen Species.
'Oxidative and Nitrative Stress in Toxicology and Disease' was the subject... | AstraZeneca R&D Safety Assessment, Alderley Park, UK. | Toxicology. 2010 Jul 16.
DOI Direct Link |
| Impact of Input Parameters on the Prediction of Hepatic Plasma Clearance Using the Well-Stirred Model.
The in vitro metabolic stability assays are indispensable for screening... | Lead Generation, DMPK and Physical Chemistry, AstraZeneca R&D Molndal, | Curr Drug Metab. 2010 Jul 15. |
| Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds.
We compare three different approaches to scale clearance (CL) from human... | DMPK, Local Discovery CNS Pain, AstraZeneca R&D Sodertalje, S-151 85 | Xenobiotica. 2010 Jul 12.
DOI Direct Link |